A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis
Yu Chen(Xijing Hospital), Gang Wang(Wuhan University), Yangfeng Ding(Shanghai Stomatological Hospital), Weili Pan, Liangzhi Xie(Sinocelltech Group (China)), Xiaowen Pang(Air Force General Hospital PLA), Xian Jiang(Nanfang Hospital), Hongzhong Jin(Chinese Academy of Medical Sciences & Peking Union Medical College), Yehong Kuang(Central South University), Juan Tao(Union Hospital), Qianjin Lu(Central South University), Furen Zhang(Shandong Provincial Institute of Dermatology and Venereology), Jun Gu(Peking University), Danqi Deng(Kunming Medical University), Yan Wang(Shanghai Medical College of Fudan University), Chunlei Zhang(Peking University), Yi Zhao(Beijing Tsinghua Chang Gung Hospital), Yumei Li(Qingdao University), Jieying Wang(Sinocelltech Group (China)), Yuzhen Li(Harbin Medical University), Shuping Guo(Shanxi Medical University), Zhiqiang Song(Southwest General Health Center), Qing Sun(Qilu Hospital of Shandong University), Qin-ping Yang(Fudan University), Xiaojing Kang(People's Hospital of Xinjiang Uygur Autonomous Region)
Cited by 12
Related Papers
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus
|Nature Genetics|2009|951
Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis
|JNCI Journal of the National Cancer Institute|1999|558
Demethylation of <i>CD40LG</i> on the Inactive X in T Cells from Women with Lupus
|The Journal of Immunology|2007|466
Induced Regulatory T Cells: Their Development, Stability, and Applications
|Trends in Immunology|2016|451